Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by MADDEN SECURITIES Corp

MADDEN SECURITIES Corp lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 45.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,200 shares of the medical research company’s stock after selling 2,630 shares during the period. MADDEN SECURITIES Corp’s holdings in Charles River Laboratories International were worth $591,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Wolff Wiese Magana LLC purchased a new position in shares of Charles River Laboratories International during the third quarter valued at approximately $32,000. Pinnacle Bancorp Inc. boosted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Assetmark Inc. grew its stake in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares during the period. Finally, ORG Wealth Partners LLC acquired a new position in Charles River Laboratories International in the 4th quarter valued at $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CRL. Bank of America decreased their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research note on Monday, February 3rd. The Goldman Sachs Group decreased their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Stock Down 2.4 %

Shares of NYSE CRL opened at $159.90 on Tuesday. The stock has a fifty day moving average price of $179.79 and a 200 day moving average price of $192.80. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12-month low of $157.41 and a 12-month high of $275.00. The company has a market cap of $8.18 billion, a P/E ratio of 20.01, a P/E/G ratio of 6.47 and a beta of 1.37.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).